In his State of the Union, Biden takes clear aim at 'Big Pharma'

PresidentBidendeliverstheStateoftheUnionaddresstoajointsessionofCongressattheU.S.CapitolonThursday.A Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor




leisure time

author：leisure time    Page View：97131
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： FDA approves world's first CRISPR
Next article： Medicare proposal to cover medical devices draws a mixed reaction